Dienogest is a Small Molecule owned by Bayer, and is involved in 26 clinical trials, of which 24 were completed, and 2 are ongoing.
Dienogest acts as progesterone receptor agonist. Dienogest acts on endometriosis by reducing the endogenous production of oestradiol and thereby suppresses the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment causing initial decidualization of endometrial tissue followed by atrophy of endometriotic lesions. Dienogest also exhibits therapeutic intervention for the treatment of dysmenorrhea due to increased progesterone receptor-binding affinity.
The revenue for Dienogest is expected to reach a total of $48m through 2026. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dienogest NPV Report.
Dienogest (Visabelle/ Visan/ Visannette/ Allurene/ Visabelle/ Dinagest) is a progestogen preparation. It is formulated as tablets and film coated tablets for oral route of adminstration. Dienogest is indicated for the treatment of endometriosis, pelvic pain associated with endometriosis, pain associated with uterine adenomyosis. Dinagest is indicated for the treatment of functional dysmenorrhea.
Mochida Pharmaceutical Overview
Mochida Pharmaceutical (Mochida) develops, manufactures, and markets pharmaceutical and healthcare products including generics, specialty pharmaceuticals, and biosimilar products. The company’s products are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, pulmonary arterial hypertension, endometriosis, adenomyosis, thrombosis, acute pancreatitis, depression and depressive symptoms, chronic pain, cancer, chronic constipation, ulcerative colitis, gout and hyperuricemia, anticoagulant, antimycotic, and others. Its products under development are intended for the treatment of ulcerative colitis, insomnia, hyperlipidemia, articular cartilage lesion, and others. The company also offers contract manufacturing of pharmaceuticals. It operates state of art manufacturing facilities in Japan involved in technology transfers and the development of new drugs. Mochida is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY110,179 million for the fiscal year ended March 2022 (FY2022), an increase of 7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.4% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 8.3% in FY2021. The company reported revenues of JPY25,508 million for the second quarter ended September 2022, a decrease of 7.9% over the previous quarter.
Quick View – Dienogest
|Highest Development Stage|